8F0I
Crystal structure of SARS-CoV-2 receptor binding domain in complex with human antibody COVA309-22
Summary for 8F0I
| Entry DOI | 10.2210/pdb8f0i/pdb |
| Descriptor | Spike protein S1, COVA309-22 heavy chain, COVA309-22 light chain, ... (4 entities in total) |
| Functional Keywords | antibody, sars-cov-2, coronavirus, rbd, covid-19, immune system, viral protein-immune system complex, viral protein/immune system |
| Biological source | Severe acute respiratory syndrome coronavirus 2 More |
| Total number of polymer chains | 9 |
| Total formula weight | 212441.69 |
| Authors | Yuan, M.,Wilson, I.A. (deposition date: 2022-11-03, release date: 2023-09-13, Last modification date: 2024-11-06) |
| Primary citation | Guerra, D.,Beaumont, T.,Radic, L.,Kerster, G.,van der Straten, K.,Yuan, M.,Torres, J.L.,Lee, W.H.,Liu, H.,Poniman, M.,Bontjer, I.,Burger, J.A.,Claireaux, M.,Caniels, T.G.,Snitselaar, J.L.,Bijl, T.P.L.,Kruijer, S.,Ozorowski, G.,Gideonse, D.,Sliepen, K.,Ward, A.B.,Eggink, D.,de Bree, G.J.,Wilson, I.A.,Sanders, R.W.,van Gils, M.J. Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual. Iscience, 26:108009-108009, 2023 Cited by PubMed Abstract: The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has remained a medical threat due to the evolution of multiple variants that acquire resistance to vaccines and prior infection. Therefore, it is imperative to discover monoclonal antibodies (mAbs) that neutralize a broad range of SARS-CoV-2 variants. A stabilized spike glycoprotein was used to enrich antigen-specific B cells from an individual with a primary Gamma variant infection. Five mAbs selected from those B cells showed considerable neutralizing potency against multiple variants, with COVA309-35 being the most potent against the autologous virus, as well as Omicron BA.1 and BA.2, and COVA309-22 having binding and neutralization activity against Omicron BA.4/5, BQ.1.1, and XBB.1. When combining the COVA309 mAbs as cocktails or bispecific antibodies, the breadth and potency were improved. In addition, the mechanism of cross-neutralization of the COVA309 mAbs was elucidated by structural analysis. Altogether these data indicate that a Gamma-infected individual can develop broadly neutralizing antibodies. PubMed: 37841584DOI: 10.1016/j.isci.2023.108009 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (3.7 Å) |
Structure validation
Download full validation report
